Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21752564 | 0.93 | KMT2A (0.49) | LIPEKMT2AALOX15CNR1ADRB2 | |
| SCHEMBL23959556 | 0.91 | KMT2A (0.44) | KMT2AALOX15KDM4ELMNAPOLB | |
| SCHEMBL23959626 | 0.90 | KMT2A (0.43) | KMT2AALOX15CNR1EPHX2KDM4E | |
| SCHEMBL23959594 | 0.90 | KMT2A (0.43) | KMT2AALOX15CNR1KDM4ESMN1; SMN2 | |
| SCHEMBL23959602 | 0.88 | KMT2A (0.40) | KMT2AALOX15CNR1ADRB2POLB | |
| SCHEMBL23959578 | 0.86 | MLNR (0.43) | KMT2AALOX15CNR1 | |
| SCHEMBL23959539 | 0.85 | KDM4E (0.41) | KMT2AALOX15EPHX2KDM4ELMNA | |
| SCHEMBL21752686 | 0.84 | KMT2A (0.47) | LIPEKMT2AALOX15CNR1EPHX2 | |
| SCHEMBL23959580 | 0.84 | CNR1 (0.42) | KMT2ACNR1EPHX2 | |
| SCHEMBL23959703 | 0.84 | ALOX15 (0.42) | KMT2AALOX15CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, KYNU | LIPE 2487/4885KMT2A 1461/4885ALOX15 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.